ARL6IP6, Human, 重组蛋白 (mFc) TMPY-00344
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | 价格 | 操作 |
---|---|---|
100 μg | ¥4,460.00 | 询底价 |
Product Introduction
Bioactivity
英文名: ARL6IP6 Protein, Human, Recombinant (mFc)
描述: It had been found that a homozygous truncating mutation in ARL6IP6 as the likely cause of a syndromic form of CMTC associated with major dysmorphism, developmental delay, transient ischemic attacks and cerebral vascular malformations. This gene was previously implicated by genome wide association study (GWAS) as a susceptibility locus to ischemic stroke in young adults. We identify ARL6IP6 as a novel candidate gene for a syndromic form of CMTC. This suggests that ischemic stroke or transient ischemic attacks (TIA) may represent, at least in some cases, the mild end of a phenotypic spectrum that has at its severe end autosomal recessive CMTC. This finding contributes to a growing appreciation of the continuum of Mendelian and common complex diseases.
存储条件: Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month
关键字: AIP6 | PFAAP 1 | AIP 6 | PFAAP-1
ARL6IP6, Human, 重组蛋白 (mFc) TMPY-00344信息由TargetMol中国为您提供,如您想了解更多关于ARL6IP6, Human, 重组蛋白 (mFc) TMPY-00344报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途